ID   BMX_HUMAN               Reviewed;         675 AA.
AC   P51813; A6NIH9; O60564; Q12871;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   12-OCT-2022, entry version 211.
DE   RecName: Full=Cytoplasmic tyrosine-protein kinase BMX;
DE            EC=2.7.10.2;
DE   AltName: Full=Bone marrow tyrosine kinase gene in chromosome X protein;
DE   AltName: Full=Epithelial and endothelial tyrosine kinase;
DE            Short=ETK;
DE   AltName: Full=NTK38;
GN   Name=BMX;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Bone marrow;
RX   PubMed=7970727;
RA   Tamagnone L., Lahtinen I., Mustonen T., Virtaneva K., Francis F.,
RA   Muscatelli F., Alitalo R.P., Smith C.I., Larsson C., Alitalo K.;
RT   "BMX, a novel nonreceptor tyrosine kinase gene of the BTK/ITK/TEC/TXK
RT   family located in chromosome Xp22.2.";
RL   Oncogene 9:3683-3688(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND INDUCTION.
RC   TISSUE=Prostate;
RX   PubMed=9520419; DOI=10.1073/pnas.95.7.3644;
RA   Qiu Y., Robinson D., Pretlow T., Kung H.-J.;
RT   "Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an
RT   effector of phosphatidylinositol 3'-kinase and is involved in interleukin
RT   6-induced neuroendocrine differentiation of prostate cancer cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:3644-3649(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 207-220 AND 223-236, AND PHOSPHORYLATION AT TYR-216 AND
RP   TYR-224.
RX   PubMed=12573241; DOI=10.1016/s1570-9639(02)00524-1;
RA   Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A.,
RA   Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.;
RT   "Identification of phosphorylation sites within the SH3 domains of Tec
RT   family tyrosine kinases.";
RL   Biochim. Biophys. Acta 1645:123-132(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 536-599.
RC   TISSUE=Blood;
RA   Fuortes M.;
RL   Thesis (1994), Cornell University, United States.
RN   [8]
RP   PHOSPHORYLATION AT TYR-566, MUTAGENESIS OF TYR-566, FUNCTION, AND
RP   INTERACTION WITH STAT3.
RX   PubMed=10688651; DOI=10.1128/mcb.20.6.2043-2054.2000;
RA   Tsai Y.T., Su Y.H., Fang S.S., Huang T.N., Qiu Y., Jou Y.S., Shih H.M.,
RA   Kung H.J., Chen R.H.;
RT   "Etk, a Btk family tyrosine kinase, mediates cellular transformation by
RT   linking Src to STAT3 activation.";
RL   Mol. Cell. Biol. 20:2043-2054(2000).
RN   [9]
RP   INDUCTION, INTERACTION WITH PTK2/FAK1, ACTIVITY REGULATION, AND FUNCTION.
RX   PubMed=11331870; DOI=10.1038/35074500;
RA   Chen R., Kim O., Li M., Xiong X., Guan J.L., Kung H.J., Chen H.,
RA   Shimizu Y., Qiu Y.;
RT   "Regulation of the PH-domain-containing tyrosine kinase Etk by focal
RT   adhesion kinase through the FERM domain.";
RL   Nat. Cell Biol. 3:439-444(2001).
RN   [10]
RP   DOMAIN, AND INTERACTION WITH CAV1.
RX   PubMed=11751885; DOI=10.1074/jbc.m108537200;
RA   Vargas L., Nore B.F., Berglof A., Heinonen J.E., Mattsson P.T., Smith C.I.,
RA   Mohamed A.J.;
RT   "Functional interaction of caveolin-1 with Bruton's tyrosine kinase and
RT   Bmx.";
RL   J. Biol. Chem. 277:9351-9357(2002).
RN   [11]
RP   INTERACTION WITH RUFY1 AND RUFY2.
RX   PubMed=11877430; DOI=10.1074/jbc.m111933200;
RA   Yang J., Kim O., Wu J., Qiu Y.;
RT   "Interaction between tyrosine kinase Etk and a RUN-domain and FYVE-domain
RT   containing protein RUFY1. A possible role of Etk in regulation of vesicle
RT   trafficking.";
RL   J. Biol. Chem. 277:30219-30226(2002).
RN   [12]
RP   ACTIVITY REGULATION, PHOSPHORYLATION, FUNCTION, AND INTERACTION WITH
RP   TNFRSF1B.
RX   PubMed=12370298; DOI=10.1128/mcb.22.21.7512-7523.2002;
RA   Pan S., An P., Zhang R., He X., Yin G., Min W.;
RT   "Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role
RT   in endothelial cell migration and angiogenesis.";
RL   Mol. Cell. Biol. 22:7512-7523(2002).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH BCAR1.
RX   PubMed=12832404; DOI=10.1074/jbc.m306438200;
RA   Abassi Y.A., Rehn M., Ekman N., Alitalo K., Vuori K.;
RT   "p130Cas Couples the tyrosine kinase Bmx/Etk with regulation of the actin
RT   cytoskeleton and cell migration.";
RL   J. Biol. Chem. 278:35636-35643(2003).
RN   [14]
RP   FUNCTION.
RX   PubMed=15788485; DOI=10.1152/ajpcell.00410.2004;
RA   Chau C.H., Clavijo C.A., Deng H.T., Zhang Q., Kim K.J., Qiu Y., Le A.D.,
RA   Ann D.K.;
RT   "Etk/Bmx mediates expression of stress-induced adaptive genes VEGF, PAI-1,
RT   and iNOS via multiple signaling cascades in different cell systems.";
RL   Am. J. Physiol. 289:C444-C454(2005).
RN   [15]
RP   PHOSPHORYLATION, ACTIVITY REGULATION, FUNCTION, AND INTERACTION WITH MYD88;
RP   PTK2/FAK1 AND TIRAP.
RX   PubMed=18292575; DOI=10.4049/jimmunol.180.5.3485;
RA   Semaan N., Alsaleh G., Gottenberg J.E., Wachsmann D., Sibilia J.;
RT   "Etk/BMX, a Btk family tyrosine kinase, and Mal contribute to the cross-
RT   talk between MyD88 and FAK pathways.";
RL   J. Immunol. 180:3485-3491(2008).
RN   [16]
RP   REVIEW ON FUNCTION.
RX   PubMed=11114746; DOI=10.1038/sj.onc.1203958;
RA   Qiu Y., Kung H.J.;
RT   "Signaling network of the Btk family kinases.";
RL   Oncogene 19:5651-5661(2000).
RN   [17]
RP   REVIEW ON FUNCTION.
RX   PubMed=11340625; DOI=10.1002/bies.1062;
RA   Smith C.I., Islam T.C., Mattsson P.T., Mohamed A.J., Nore B.F., Vihinen M.;
RT   "The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk,
RT   Tec, Txk and homologs in other species.";
RL   Bioessays 23:436-446(2001).
RN   [18]
RP   REVIEW ON FUNCTION.
RX   PubMed=17624943; DOI=10.1111/j.1600-065x.2007.00534.x;
RA   Gomez-Rodriguez J., Readinger J.A., Viorritto I.C., Mueller K.L.,
RA   Houghtling R.A., Schwartzberg P.L.;
RT   "Tec kinases, actin, and cell adhesion.";
RL   Immunol. Rev. 218:45-64(2007).
RN   [19]
RP   STRUCTURE BY NMR OF 112-393.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the human BMX SH2 domain and of the BTK motif of
RT   human cytoplasmic tyrosine-protein kinase BMX.";
RL   Submitted (OCT-2007) to the PDB data bank.
RN   [20]
RP   STRUCTURE BY NMR OF 291-393.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the human bmx SH2 domain.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-284 AND TRP-670.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine kinase that plays central but diverse
CC       modulatory roles in various signaling processes involved in the
CC       regulation of actin reorganization, cell migration, cell proliferation
CC       and survival, cell adhesion, and apoptosis. Participates in signal
CC       transduction stimulated by growth factor receptors, cytokine receptors,
CC       G-protein coupled receptors, antigen receptors and integrins. Induces
CC       tyrosine phosphorylation of BCAR1 in response to integrin regulation.
CC       Activation of BMX by integrins is mediated by PTK2/FAK1, a key mediator
CC       of integrin signaling events leading to the regulation of actin
CC       cytoskeleton and cell motility. Plays a critical role in TNF-induced
CC       angiogenesis, and implicated in the signaling of TEK and FLT1
CC       receptors, 2 important receptor families essential for angiogenesis.
CC       Required for the phosphorylation and activation of STAT3, a
CC       transcription factor involved in cell differentiation. Also involved in
CC       interleukin-6 (IL6) induced differentiation. Also plays a role in
CC       programming adaptive cytoprotection against extracellular stress in
CC       different cell systems, salivary epithelial cells, brain endothelial
CC       cells, and dermal fibroblasts. May be involved in regulation of
CC       endocytosis through its interaction with an endosomal protein RUFY1.
CC       May also play a role in the growth and differentiation of hematopoietic
CC       cells; as well as in signal transduction in endocardial and arterial
CC       endothelial cells. {ECO:0000269|PubMed:10688651,
CC       ECO:0000269|PubMed:11331870, ECO:0000269|PubMed:12370298,
CC       ECO:0000269|PubMed:12832404, ECO:0000269|PubMed:15788485,
CC       ECO:0000269|PubMed:18292575, ECO:0000269|PubMed:9520419}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- ACTIVITY REGULATION: TEK and vascular endothelial growth factor
CC       receptor 1 (FLT1) stimulate BMX tyrosine kinase activity (By
CC       similarity). Activated by integrins through the mediation of PTK2/FAK1.
CC       Activated by TNF through the mediation of TNFRSF1B. {ECO:0000250,
CC       ECO:0000269|PubMed:11331870, ECO:0000269|PubMed:12370298,
CC       ECO:0000269|PubMed:18292575}.
CC   -!- SUBUNIT: Interacts with BCAR1, CAV1, MYD88, PTK2/FAK1, RUFY1, RUFY2,
CC       STAT3, TIRAP and TNFRSF1B. {ECO:0000269|PubMed:10688651,
CC       ECO:0000269|PubMed:11331870, ECO:0000269|PubMed:11751885,
CC       ECO:0000269|PubMed:11877430, ECO:0000269|PubMed:12370298,
CC       ECO:0000269|PubMed:12832404, ECO:0000269|PubMed:18292575}.
CC   -!- INTERACTION:
CC       P51813; Q13490: BIRC2; NbExp=3; IntAct=EBI-696657, EBI-514538;
CC       P51813; P08238: HSP90AB1; NbExp=3; IntAct=EBI-696657, EBI-352572;
CC       P51813; P11309: PIM1; NbExp=2; IntAct=EBI-696657, EBI-696621;
CC       P51813; P11309-2: PIM1; NbExp=6; IntAct=EBI-696657, EBI-1018633;
CC       P51813; Q16825: PTPN21; NbExp=3; IntAct=EBI-696657, EBI-2860264;
CC       P51813; P40763: STAT3; NbExp=8; IntAct=EBI-696657, EBI-518675;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12832404}.
CC       Note=Localizes to the edges of spreading cells when complexed with
CC       BCAR1.
CC   -!- TISSUE SPECIFICITY: Highly expressed in cells with great migratory
CC       potential, including endothelial cells and metastatic carcinoma cell
CC       lines.
CC   -!- INDUCTION: Activated by IL6/interleukin-6 through phosphatidylinositol
CC       3-kinase (PI3-kinase) pathway. It is likely that activation occurs
CC       through binding of phosphoinositides to the PH domain.
CC       {ECO:0000269|PubMed:11331870, ECO:0000269|PubMed:9520419}.
CC   -!- DOMAIN: SH2 domain mediates interaction with RUFY1.
CC       {ECO:0000269|PubMed:11751885}.
CC   -!- PTM: Phosphorylated in response to protein I/II and to LPS.
CC       Phosphorylation at Tyr-566 by SRC and by autocatalysis leads to
CC       activation and is required for STAT3 phosphorylation by BMX.
CC       {ECO:0000269|PubMed:10688651, ECO:0000269|PubMed:12370298,
CC       ECO:0000269|PubMed:12573241, ECO:0000269|PubMed:18292575}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. TEC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC08966.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X83107; CAA58169.1; -; mRNA.
DR   EMBL; AF045459; AAC08966.1; ALT_INIT; mRNA.
DR   EMBL; AC097625; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471074; EAW98889.1; -; Genomic_DNA.
DR   EMBL; BC016652; AAH16652.1; -; mRNA.
DR   EMBL; U08341; AAA17744.1; -; mRNA.
DR   CCDS; CCDS14168.1; -.
DR   PIR; S60612; S60612.
DR   RefSeq; NP_001307795.1; NM_001320866.1.
DR   RefSeq; NP_001712.1; NM_001721.6.
DR   RefSeq; NP_975010.1; NM_203281.2.
DR   PDB; 2EKX; NMR; -; A=291-393.
DR   PDB; 2YS2; NMR; -; A=113-149.
DR   PDB; 3SXR; X-ray; 2.40 A; A/B=411-675.
DR   PDB; 3SXS; X-ray; 1.89 A; A=411-675.
DR   PDB; 6I99; X-ray; 2.00 A; A/B=411-675.
DR   PDBsum; 2EKX; -.
DR   PDBsum; 2YS2; -.
DR   PDBsum; 3SXR; -.
DR   PDBsum; 3SXS; -.
DR   PDBsum; 6I99; -.
DR   AlphaFoldDB; P51813; -.
DR   SMR; P51813; -.
DR   BioGRID; 107128; 72.
DR   IntAct; P51813; 77.
DR   MINT; P51813; -.
DR   STRING; 9606.ENSP00000350224; -.
DR   BindingDB; P51813; -.
DR   ChEMBL; CHEMBL3834; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB15035; Zanubrutinib.
DR   DrugCentral; P51813; -.
DR   GuidetoPHARMACOLOGY; 1942; -.
DR   iPTMnet; P51813; -.
DR   PhosphoSitePlus; P51813; -.
DR   BioMuta; BMX; -.
DR   DMDM; 1705489; -.
DR   EPD; P51813; -.
DR   jPOST; P51813; -.
DR   MassIVE; P51813; -.
DR   MaxQB; P51813; -.
DR   PaxDb; P51813; -.
DR   PeptideAtlas; P51813; -.
DR   PRIDE; P51813; -.
DR   ProteomicsDB; 56409; -.
DR   Antibodypedia; 412; 654 antibodies from 33 providers.
DR   DNASU; 660; -.
DR   Ensembl; ENST00000342014.6; ENSP00000340082.6; ENSG00000102010.15.
DR   Ensembl; ENST00000348343.11; ENSP00000308774.6; ENSG00000102010.15.
DR   Ensembl; ENST00000357607.6; ENSP00000350224.2; ENSG00000102010.15.
DR   GeneID; 660; -.
DR   KEGG; hsa:660; -.
DR   MANE-Select; ENST00000348343.11; ENSP00000308774.6; NM_203281.3; NP_975010.1.
DR   UCSC; uc004cww.3; human.
DR   CTD; 660; -.
DR   DisGeNET; 660; -.
DR   GeneCards; BMX; -.
DR   HGNC; HGNC:1079; BMX.
DR   HPA; ENSG00000102010; Tissue enriched (epididymis).
DR   MIM; 300101; gene.
DR   neXtProt; NX_P51813; -.
DR   OpenTargets; ENSG00000102010; -.
DR   PharmGKB; PA25389; -.
DR   VEuPathDB; HostDB:ENSG00000102010; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   GeneTree; ENSGT00940000161172; -.
DR   HOGENOM; CLU_000288_7_2_1; -.
DR   InParanoid; P51813; -.
DR   OMA; VPILRMD; -.
DR   PhylomeDB; P51813; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; P51813; -.
DR   Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   SignaLink; P51813; -.
DR   SIGNOR; P51813; -.
DR   BioGRID-ORCS; 660; 11 hits in 714 CRISPR screens.
DR   ChiTaRS; BMX; human.
DR   EvolutionaryTrace; P51813; -.
DR   GeneWiki; BMX_(gene); -.
DR   GenomeRNAi; 660; -.
DR   Pharos; P51813; Tchem.
DR   PRO; PR:P51813; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P51813; protein.
DR   Bgee; ENSG00000102010; Expressed in corpus epididymis and 106 other tissues.
DR   Genevisible; P51813; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0032587; C:ruffle membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0002250; P:adaptive immune response; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0007498; P:mesoderm development; TAS:ProtInc.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   CDD; cd10399; SH2_Tec_Bmx; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR028840; BMX.
DR   InterPro; IPR035875; BMX_SH2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001562; Znf_Btk_motif.
DR   PANTHER; PTHR24418:SF91; PTHR24418:SF91; 2.
DR   Pfam; PF00779; BTK; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00402; TECBTKDOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00107; BTK; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS51113; ZF_BTK; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; ATP-binding; Cell adhesion; Cytoplasm;
KW   Direct protein sequencing; Kinase; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Reference proteome; SH2 domain; Stress response;
KW   Transferase; Tyrosine-protein kinase; Zinc; Zinc-finger.
FT   CHAIN           1..675
FT                   /note="Cytoplasmic tyrosine-protein kinase BMX"
FT                   /id="PRO_0000088063"
FT   DOMAIN          4..111
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          296..392
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          417..675
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ZN_FING         113..149
FT                   /note="Btk-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432"
FT   MOTIF           596..603
FT                   /note="CAV1-binding"
FT   ACT_SITE        536
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         121
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432"
FT   BINDING         132
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432"
FT   BINDING         133
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432"
FT   BINDING         143
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432"
FT   BINDING         423..431
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         445
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         216
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12573241"
FT   MOD_RES         224
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12573241"
FT   MOD_RES         566
FT                   /note="Phosphotyrosine; by SRC and autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:10688651"
FT   VARIANT         284
FT                   /note="S -> L (in dbSNP:rs35353387)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041674"
FT   VARIANT         670
FT                   /note="R -> W (in a lung large cell carcinoma sample;
FT                   somatic mutation; dbSNP:rs1029888196)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041675"
FT   MUTAGEN         566
FT                   /note="Y->F: Abolishes almost completely the SRC-induced
FT                   phosphorylation of BMX."
FT                   /evidence="ECO:0000269|PubMed:10688651"
FT   CONFLICT        207
FT                   /note="P -> G (in Ref. 6; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        597
FT                   /note="A -> S (in Ref. 7; AAA17744)"
FT                   /evidence="ECO:0000305"
FT   STRAND          129..133
FT                   /evidence="ECO:0007829|PDB:2YS2"
FT   STRAND          136..139
FT                   /evidence="ECO:0007829|PDB:2YS2"
FT   STRAND          294..297
FT                   /evidence="ECO:0007829|PDB:2EKX"
FT   HELIX           303..312
FT                   /evidence="ECO:0007829|PDB:2EKX"
FT   STRAND          318..323
FT                   /evidence="ECO:0007829|PDB:2EKX"
FT   STRAND          330..334
FT                   /evidence="ECO:0007829|PDB:2EKX"
FT   STRAND          347..350
FT                   /evidence="ECO:0007829|PDB:2EKX"
FT   STRAND          359..362
FT                   /evidence="ECO:0007829|PDB:2EKX"
FT   HELIX           370..379
FT                   /evidence="ECO:0007829|PDB:2EKX"
FT   STRAND          383..385
FT                   /evidence="ECO:0007829|PDB:2EKX"
FT   HELIX           414..416
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   STRAND          417..426
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   STRAND          429..436
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   TURN            437..439
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   STRAND          440..447
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   HELIX           454..466
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   STRAND          475..479
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   STRAND          481..490
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   HELIX           497..504
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   HELIX           505..507
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   HELIX           510..529
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   STRAND          532..536
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   HELIX           539..541
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   STRAND          542..544
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   STRAND          550..552
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   TURN            555..557
FT                   /evidence="ECO:0007829|PDB:3SXR"
FT   STRAND          558..560
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   STRAND          566..568
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   HELIX           576..578
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   HELIX           581..586
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   STRAND          587..590
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   HELIX           593..606
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   TURN            607..609
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   TURN            612..615
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   HELIX           618..626
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   HELIX           639..647
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   HELIX           653..655
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   HELIX           659..666
FT                   /evidence="ECO:0007829|PDB:3SXS"
FT   HELIX           667..669
FT                   /evidence="ECO:0007829|PDB:3SXS"
SQ   SEQUENCE   675 AA;  78011 MW;  CB22382A3BD02599 CRC64;
     MDTKSILEEL LLKRSQQKKK MSPNNYKERL FVLTKTNLSY YEYDKMKRGS RKGSIEIKKI
     RCVEKVNLEE QTPVERQYPF QIVYKDGLLY VYASNEESRS QWLKALQKEI RGNPHLLVKY
     HSGFFVDGKF LCCQQSCKAA PGCTLWEAYA NLHTAVNEEK HRVPTFPDRV LKIPRAVPVL
     KMDAPSSSTT LAQYDNESKK NYGSQPPSSS TSLAQYDSNS KKIYGSQPNF NMQYIPREDF
     PDWWQVRKLK SSSSSEDVAS SNQKERNVNH TTSKISWEFP ESSSSEEEEN LDDYDWFAGN
     ISRSQSEQLL RQKGKEGAFM VRNSSQVGMY TVSLFSKAVN DKKGTVKHYH VHTNAENKLY
     LAENYCFDSI PKLIHYHQHN SAGMITRLRH PVSTKANKVP DSVSLGNGIW ELKREEITLL
     KELGSGQFGV VQLGKWKGQY DVAVKMIKEG SMSEDEFFQE AQTMMKLSHP KLVKFYGVCS
     KEYPIYIVTE YISNGCLLNY LRSHGKGLEP SQLLEMCYDV CEGMAFLESH QFIHRDLAAR
     NCLVDRDLCV KVSDFGMTRY VLDDQYVSSV GTKFPVKWSA PEVFHYFKYS SKSDVWAFGI
     LMWEVFSLGK QPYDLYDNSQ VVLKVSQGHR LYRPHLASDT IYQIMYSCWH ELPEKRPTFQ
     QLLSSIEPLR EKDKH
//
